Valuation: Pharmigene, Inc.

Market Cap 353M 10.89M 9.58M 8.9M 8.19M 15.35M 1.06B 15.63M 106M 41.52M 515M 40.9M 40.02M 1.79B P/E 2024
-8.68x
P/E 2025 -6.84x
Enterprise Value 922M 28.49M 25.05M 23.28M 21.41M 40.14M 2.76B 40.86M 278M 109M 1.35B 107M 105M 4.67B EV / Sales 2024
10.1x
EV / Sales 2025 5.35x
Free-Float
49.29%
Yield 2024 *
-
Yield 2025 -
1 day-5.03%
1 week+10.95%
Current month-3.85%
1 month-9.22%
3 months-33.43%
6 months-26.88%
Current year-29.39%
1 week 6.65
Extreme 6.65
9.35
1 month 5.9
Extreme 5.9
9.35
Current year 5.9
Extreme 5.9
11.85
1 year 5.9
Extreme 5.9
14.1
3 years 5.9
Extreme 5.9
25.7
5 years 5.9
Extreme 5.9
25.7
10 years 5.9
Extreme 5.9
36
Manager TitleAgeSince
Chief Executive Officer 67 2019-11-03
Chief Operating Officer 49 2019-11-03
Comptroller/Controller/Auditor - -
Director TitleAgeSince
Director/Board Member 76 2020-11-23
Director/Board Member 49 2019-11-03
Chairman 67 -
Change 5-day change 1-year change 3-year change Capi.($)
-5.03%+10.95%-38.41%-69.87% 11.45M
-0.22%-2.74%+146.19%+102.52% 4.63B
+1.64%-2.58%+111.87%+176.11% 3.51B
-0.77%+8.23%+63.90%-33.12% 2.31B
-1.76%-1.45%-27.07%-36.48% 2.13B
-0.45%+26.42%+188.86%+253.81% 1.95B
-0.70%+0.14%+178.66%-43.60% 1.05B
+2.42%-5.81%-8.77%+28.14% 830M
+0.67%-1.89%-36.38%-13.58% 494M
+6.72%-12.13%-7.56% - 407M
Average +0.25%-0.51%+57.13%+40.44% 1.73B
Weighted average by Cap. +0.15%+2.60%+97.40%+83.08%

Financials

2024 2025
Net sales 117M 3.6M 3.17M 2.94M 2.7M 5.07M 349M 5.16M 35.16M 13.72M 170M 13.51M 13.22M 590M 200M 6.17M 5.43M 5.04M 4.64M 8.7M 598M 8.86M 60.32M 23.53M 292M 23.18M 22.68M 1.01B
Net income -82.86M -2.56M -2.25M -2.09M -1.92M -3.61M -248M -3.67M -25M -9.75M -121M -9.61M -9.4M -419M -73M -2.25M -1.98M -1.84M -1.69M -3.18M -218M -3.23M -22.03M -8.59M -106M -8.46M -8.28M -369M
Net Debt 458M 14.14M 12.44M 11.55M 10.63M 19.93M 1.37B 20.28M 138M 53.89M 668M 53.09M 51.94M 2.32B 570M 17.59M 15.47M 14.37M 13.22M 24.79M 1.7B 25.24M 172M 67.04M 831M 66.04M 64.62M 2.88B
Logo Pharmigene, Inc.
Pharmigene Inc is mainly engaged in drug gene diagnosis, functional medical testing services and agency sales of laboratory equipment and consumables. The Company mainly engages in field of genomics science, developing professional drug genetic diagnostic kits, testing technologies, and overall solutions for the research and development of drug genomics in precision medicine. The Company's molecular diagnostic products mainly include AutoEx16 automatic nucleic acid extractor, Clopidogrel drug effectiveness gene CYP2C19*2&*3 test kit, SGE 1502 test suite, SGE 3101 test suite, SGE 5701 test suite, Sega 5801 test kit, SGE B27 test kit, SGE whole blood calculation and extraction kit and others. Testing services include drug genetic testing projects, functional medical testing projects and personalized genetic testing. The Company mainly distributes its products in Taiwan market and other markets.
Employees
-
Date Price Change Volume
26-07-23 NT$6.990 -5.03% 194,124
26-07-22 NT$7.360 -4.17% 12,510
26-07-21 NT$7.680 -0.65% 184,091
26-07-20 NT$7.730 -13.63% 198,235
26-07-17 NT$8.950 +10.49% 255,559
  1. Stock Market
  2. Stocks
  3. 7595 Stock